Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can big data unmask hidden clusters of cardiometabolic disease?

NCT ID NCT07781371

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study looks at anonymized health records from about 100,000 people in a Turkish hospital network to see how common cardiometabolic conditions—like obesity, type 2 diabetes, heart disease, fatty liver, and kidney disease—are and how often they occur together. By tracking these patterns from 2022 to 2025, researchers hope to identify distinct clusters of patients and understand their typical characteristics, lab results, and treatments. No new treatment is given; the goal is purely to learn from real-world data to guide future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could reveal how often major cardiometabolic diseases occur together, helping doctors spot high-risk patient groups and tailor prevention or treatment strategies.
What could go wrong
Because it relies on existing medical records, data may be incomplete or inconsistent, and findings from one hospital network in Turkey may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

SCALA cohort

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged above or equal to 12 years at index date. * Participants with international classification of diseases (ICD-10) coded diagnosis or secondary criteria for either diabetes (type 2 diabetes, pre-diabetes), overweight, obesity, metabolic dysfunction-associated steatotic liver disease (or non-alcoholic fatty liver disease), cardiovascular disease (arterial hypertension, ischemic heart disease, myocardial infarction, heart failure, cerebrovascular disease (including stroke and transient ischemic attack), atherosclerosis, atrial fibrillation), chronic kidney disease, dyslipidemia. * At least one healthcare encounter within 12 months prior to index date (pre-index) to ensure availability of baseline data. Exclusion Criteria: * None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease (CVD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease chronic renal failure syndrome Dyslipidemias inherited lipid metabolism disorder metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease (CVD) Chronic kidney disease (CKD) Dyslipidemia Metabolic dysfunction-associated steatotic liver disease (masld) Obesity Prediabetes Type 2 diabetes (T2D)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Novo Nordisk Investigational Site

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.